Subscribe
istock-ciphotos-istockphoto-com665048016-1-
CIPhotos / iStockphoto.com
31 January 2019Americas

Celgene signs $1bn deal to develop blood cancer therapy

Global biopharmaceutical company Celgene has signed a collaboration deal worth up to nearly $1 billion to develop a preclinical therapeutic for the treatment of blood cancers, including leukaemia.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Celgene reveals plans to acquire Juno for $9bn
23 January 2018   Celgene and Juno Therapeutics announced yesterday that they have entered into a deal that will see Celgene acquire Juno.
Big Pharma
Celgene settles antitrust class-action for $55m
25 July 2019   US biotech company Celgene has agreed to pay a $55 million settlement after it was accused of illegally maintaining a monopoly over the market for its cancer treatments.


Editor's picks

Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

Editor's picks

Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Americas
Litigation implications of the USPTO’s terminal disclaimer proposal
29 August 2024
Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024
Europe
Labour govt appoints new Minister with IP oversight
9 July 2024
Americas
New-look WIPR Leaders 2024 is ‘most rigorous’ yet
2 July 2024
Americas
Earthquake Chevron: A massive shock to the system?
2 July 2024

More on this story

Americas
Celgene reveals plans to acquire Juno for $9bn
23 January 2018   Celgene and Juno Therapeutics announced yesterday that they have entered into a deal that will see Celgene acquire Juno.
Big Pharma
Celgene settles antitrust class-action for $55m
25 July 2019   US biotech company Celgene has agreed to pay a $55 million settlement after it was accused of illegally maintaining a monopoly over the market for its cancer treatments.

More on this story

Americas
Celgene reveals plans to acquire Juno for $9bn
23 January 2018   Celgene and Juno Therapeutics announced yesterday that they have entered into a deal that will see Celgene acquire Juno.
Big Pharma
Celgene settles antitrust class-action for $55m
25 July 2019   US biotech company Celgene has agreed to pay a $55 million settlement after it was accused of illegally maintaining a monopoly over the market for its cancer treatments.

More features

Gilead scores win in fake HIV drug dispute
Polsinelli grows roster with ex-corporate counsel
‘Don’t rely on national case law’ at the UPC: Wouter Pors, Bird & Bird
Sandoz wins $137.2m payout for lost profits in generic launch
Sanofi signs global rights deal to develop rare cancer therapy
Unified Patent Court visualised: Cases, divisions, and classes in charts
WBD to merge with firm to create ‘powerhouse’ practice
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers